The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24

Keyphrases

• Quadrivalent 100%
• HPV6 100%
• Human Papillomavirus 6 100%
• European Women 100%
• Virus-like 100%
• Per-protocol 40%
• HPV Types 40%
• Chimeric VLPs 40%
• VLP Vaccine 40%
• 95% Confidence Interval 40%
• Placebo 20%
• European Population 20%
• Female Subjects 20%
• Sexually Active 20%
• Carcinoma in Situ 20%
• Condyloma 20%
• Vaccine Effectiveness 20%
• Highly Effective 20%
• HPV-related Cancers 20%
• Vaccination Program 20%
• Vulvar Intraepithelial Neoplasia 20%
• Genital Diseases 20%
• Papanicolaou Test 20%
• External Genital Lesions 20%
• Vulvar Cancer 20%
• Vaginal Cancer 20%
• External Genitalia 20%
• Anti-HPV 20%
• Genital Lesions 20%
• Quadrivalent HPV Vaccine 20%
• Cervicovaginal 20%
• Cervista 20%
• Cervical Cancer Precursors 20%
• Cancer-associated 20%
• Serological Tests 20%
• Lifetime Sexual Partners 20%
• Vaginal Intraepithelial Neoplasia (VaIN) 20%
• Cervical Intraepithelial Neoplasia Grade 2 (CIN2) 20%
• HPV DNA Test 20%
• Human Papillomavirus, HPV 20%

Medicine and Dentistry

• Human Papillomavirus Type 6 100%
• Virus Like Particle Vaccine 100%
• Placebo 16%
• Wart Virus 16%
• Cervical Cancer 16%
• Precursor 16%
• Lifespan 16%
• Condyloma 16%
• Adenocarcinoma in Situ 16%
• Cervical Intraepithelial Neoplasia 16%
• Vaginal Intraepithelial Neoplasia 16%
• Vulvar Intraepithelial Neoplasia 16%
• Vulvar Cancer 16%
• Vagina Cancer 16%
• Diseases 16%
• Vaccine Efficacy 16%

Immunology and Microbiology

• Human Papillomavirus Type 6 100%
• Virus Like Particle Vaccine 100%
• HPV Vaccine 33%
• Lifespan 16%
• Vaccine Efficacy 16%
• Condyloma 16%
• Precursor 16%
• Serology 16%
• Wart Virus 16%